Intercept (ICPT) extends strategic partnership with TARGET Pharma Solutions

TARGET PharmaSolutions, a real-world clinical data company, recently announced that Intercept has extended its strategic partnership for TARGET-NASH to a multi-year agreement.

TARGET-NASH is a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). TARGET-NASH is collecting retrospective and prospective data on its enrolled patients and is developing a biorepository which its stakeholders can access for translational studies (including those of genomics and biomarkers).  To date, TARGET-NASH has enrolled 2,364 patients at 55 sites.  There have been multiple presentations on TARGET-NASH at leading academic conferences and a methodology publication is currently in press. TARGET-NASH plans to enroll up to 15,000 patients over the coming years.  TARGET-NASH is led by an academic steering committee chaired by Drs. Arun Sanyal, MD (Virginia Commonwealth University); Ken Cusi, MD (University of Florida), and Brent Tetri (St. Louis University).

Meg Powell, CEO of TARGET PharmaSolutions, stated "We are pleased to extend our partnership with Intercept for TARGET-NASH.  We are developing valuable real-world data and insight on the NASHpatient population.  Our industry partners are benefitting from their participation in TARGET-NASH as each company works to enhance its understanding of this increasingly prevalent disease and to progress its NASH development program.  We are excited to have the opportunity to assist our industry partners in these critical efforts."